
Tivorsan Pharmaceuticals is working with a Brown University team to optimize recombinant biglycan for delivery to patients with Duchenne muscular dystrophy. The work builds on the researchers' finding that the extracellular matrix glycoprotein decreases muscle pathology and improves muscle function in dystrophic mice.
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
